Ann: Acrux completes enrolment in Phase 3 trial o, page-3

re: Ann: Acrux completes enrolment in Phase 3... When I saw that announcement, at first I thought Acrux had pulled a secret drug development program out of the hat!

Nothing is guaranteed, but the phase III seem unlikely to fail.

Looking at total market sizes is misleading, but even so Axiron should be worth a similar amount to Evamist. A pre-registration partner could well pay multiples of Acrux's current market cap for it - on top of which there'd be a royalty on sales and, with the Orion manufacturing deal, a take at that end as well.